Christian Jorgensen

Summary

Country: France

Publications

  1. doi request reprint Multipotent mesenchymal stromal cells in articular diseases
    Christian Jorgensen
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, Montpellier F 34091, France
    Best Pract Res Clin Rheumatol 22:269-84. 2008
  2. ncbi request reprint Mesenchymal stem cells and rheumatoid arthritis
    Christian Jorgensen
    Immunorheumatology Department, Lapeyronie Hospital, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 70:483-5. 2003
  3. doi request reprint miRNAs and rheumatoid arthritis - promising novel biomarkers
    Isabelle Duroux-Richard
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Swiss Med Wkly 141:w13175. 2011
  4. pmc Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis
    Isabelle Duroux-Richard
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5, France Université Montpellier I, UFR de Medecine, Boulevard Henri IV, 34090 Montpellier, France
    Mediators Inflamm 2014:342524. 2014
  5. doi request reprint [Multipotent stromal cells: controversial impact on tumor development and metastasis]
    Florence Apparailly
    INSERM, U844, INM, Hopital Saint Eloi, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Med Sci (Paris) 24:359-60. 2008
  6. doi request reprint MicroRNAs as new player in rheumatoid arthritis
    Isabelle Duroux-Richard
    INSERM, U844, CHU Saint Eloi, bâtiment INM, 80, rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 78:17-22. 2011
  7. ncbi request reprint Leflunomide-induced aseptic meningitis
    Jean David Cohen
    Immuno Rheumatology Department, Hopital Lapeyronie, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 71:243-5. 2004
  8. pmc Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells
    Farida Djouad
    INSERM Unit 475, Montpellier, France
    Arthritis Res Ther 7:R1304-15. 2005
  9. ncbi request reprint Mesenchymal stem cells: an emerging tool for cancer targeting and therapy
    Vanessa Fritz
    INSERM U844, CHU Hôpital Saint Eloi Bâtiment INM, BP74103, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
    Curr Stem Cell Res Ther 3:32-42. 2008
  10. ncbi request reprint Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes
    Caroline Desmetz
    Institut de Génétique Humaine du CNRS UPR1142, Montpellier, F 34000, France
    Clin Immunol 123:148-54. 2007

Collaborators

Detail Information

Publications29

  1. doi request reprint Multipotent mesenchymal stromal cells in articular diseases
    Christian Jorgensen
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, Montpellier F 34091, France
    Best Pract Res Clin Rheumatol 22:269-84. 2008
    ..This chapter focuses on the potential of MSC to repair cartilage, with an emphasis on the factors that are known to be required in inducing chondrogenesis and on their immunosuppressive potential...
  2. ncbi request reprint Mesenchymal stem cells and rheumatoid arthritis
    Christian Jorgensen
    Immunorheumatology Department, Lapeyronie Hospital, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 70:483-5. 2003
  3. doi request reprint miRNAs and rheumatoid arthritis - promising novel biomarkers
    Isabelle Duroux-Richard
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Swiss Med Wkly 141:w13175. 2011
    ..As a growing body of evidences reveals abnormal expression of specific miRNAs in RA tissues, the use of a blood-based miRNA signature for optimal diagnosis and treatment becomes a realistic option...
  4. pmc Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis
    Isabelle Duroux-Richard
    INSERM U844, CHU Saint Eloi, bâtiment INM, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5, France Université Montpellier I, UFR de Medecine, Boulevard Henri IV, 34090 Montpellier, France
    Mediators Inflamm 2014:342524. 2014
    ..Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment. ..
  5. doi request reprint [Multipotent stromal cells: controversial impact on tumor development and metastasis]
    Florence Apparailly
    INSERM, U844, INM, Hopital Saint Eloi, 80 rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Med Sci (Paris) 24:359-60. 2008
  6. doi request reprint MicroRNAs as new player in rheumatoid arthritis
    Isabelle Duroux-Richard
    INSERM, U844, CHU Saint Eloi, bâtiment INM, 80, rue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 78:17-22. 2011
    ..Here, we provide an overview of the state-of-the-art on miRNAs in RA, focusing on both systemic and local features of the pathology...
  7. ncbi request reprint Leflunomide-induced aseptic meningitis
    Jean David Cohen
    Immuno Rheumatology Department, Hopital Lapeyronie, 34295 Montpellier Cedex 5, France
    Joint Bone Spine 71:243-5. 2004
    ..Drug-induced aseptic meningitis is uncommon and occurs primarily in patients with autoimmune disease. We report the first known case of leflunomide-induced aseptic meningitis, in a patient with rheumatoid arthritis...
  8. pmc Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells
    Farida Djouad
    INSERM Unit 475, Montpellier, France
    Arthritis Res Ther 7:R1304-15. 2005
    ....
  9. ncbi request reprint Mesenchymal stem cells: an emerging tool for cancer targeting and therapy
    Vanessa Fritz
    INSERM U844, CHU Hôpital Saint Eloi Bâtiment INM, BP74103, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
    Curr Stem Cell Res Ther 3:32-42. 2008
    ..This review highlights recent works and potential clinical applications of MSCs in this field...
  10. ncbi request reprint Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes
    Caroline Desmetz
    Institut de Génétique Humaine du CNRS UPR1142, Montpellier, F 34000, France
    Clin Immunol 123:148-54. 2007
    ..The CCR5 density on T cell surface, which is constant over time for a given individual, but varies drastically from one individual to another, might thus be a factor determining the intensity of joint inflammation in the course of RA...
  11. pmc Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005
    Alan Tyndall
    Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH 4012, Switzerland
    Arthritis Res Ther 9:301. 2007
    ..This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts...
  12. ncbi request reprint Multipotent mesenchymal stromal cells and immune tolerance
    Daniele Noel
    Universite Montpellier 1, Montpellier, France
    Leuk Lymphoma 48:1283-9. 2007
    ..Finally, the data obtained from in vivo experimentation in various animal models as well as potential therapeutic applications will be presented...
  13. ncbi request reprint RNAi in arthritis: prospects of a future antisense therapy in inflammation
    Maroun Khoury
    Inserm U 844, INM Hôpital Saint Eloi, BP 74103, 80 rue Augustin Fliche, 34091 Montpellier Cedex 5, France
    Curr Opin Mol Ther 9:483-9. 2007
    ..In addition, RNAi and current biotherapies used in the clinic are compared and contrasted...
  14. ncbi request reprint Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells
    Bruno Delorme
    INSERM, Equipe ESPRI EA 3855, Faculty of Medicine, University Francois Rabelais, 10 boulevard Tonnelle, Tours, France
    Blood 111:2631-5. 2008
    ..In addition, the expression of CD73, CD146, and CD200 was down-regulated in differentiated cells. The new marker CD200, because of its specificity and immunomodulatory properties, deserves further in-depth studies...
  15. doi request reprint Transient down-regulation of cbfa1/Runx2 by RNA interference in murine C3H10T1/2 mesenchymal stromal cells delays in vitro and in vivo osteogenesis, but does not overtly affect chondrogenesis
    Jan O Gordeladze
    Institute of Basal Medical Sciences, Department of Biochemistry, University of Oslo, Norway
    Exp Cell Res 314:1495-506. 2008
    ..These experiments indicate that a major transient reduction of cbfa1/Runx2 expression in MSCs is sufficient to delay osteoblastic differentiation, both in vitro and in vivo, while chondrogenesis seemed to be sustained...
  16. doi request reprint Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials
    Daniele Noel
    INSERM U844, Montpellier, F 34091 France
    Exp Cell Res 314:1575-84. 2008
    ..In summary, our observations indicate that ADSC and MSC are fundamentally different cell types and differently committed cells...
  17. ncbi request reprint Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism
    Farida Djouad
    Institut National de la Sante et de la Recherche Medicale, U 844, Hopital Saint Eloi, Bât INM, 80 avenue Augustin Fliche, Montpellier, France
    Stem Cells 25:2025-32. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  18. ncbi request reprint Engineered mesenchymal stem cells for cartilage repair
    Farida Djouad
    INSERM, U 475, 99 rue Puech Villa, 34197 Montpellier Cedex 5, France
    Regen Med 1:529-37. 2006
    ..Here, we focus on the potential of MSCs to repair cartilage with an emphasis on the factors that are known to be required in inducing chondrogenesis...
  19. ncbi request reprint Gene therapy for rheumatoid arthritis
    Natacha Bessis
    UPRES EA 3408 Université Paris 13 and Service de Rhumatologie CHU Avicenne, AP HP, Bobigny, France
    J Gene Med 4:581-91. 2002
    ..The best target remains to be determined and extensive research has to be conducted in preclinical studies...
  20. ncbi request reprint Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
    Farida Djouad
    INSERM U475, 99 rue Puech Villa, 34197 Montpellier Cedex 5, France
    Blood 102:3837-44. 2003
    ..Although the potential side effects of immunosuppression induced by MSCs have to be considered in further clinical studies, the usefulness of MSCs for various therapeutic applications still remains of great interest...
  21. ncbi request reprint Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells
    Daniele Noel
    INSERM U475, Montpellier, France
    Stem Cells 22:74-85. 2004
    ....
  22. ncbi request reprint Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis
    Yea Lih Lin
    Institut de Genetique Humaine, CNRS UPR1142, 34396 Montpellier Cedex 5, France
    Hum Gene Ther 15:588-96. 2004
    ..FIV vectors appear to be promising tools for biologic research and gene therapy...
  23. ncbi request reprint Tissue engineering through autologous mesenchymal stem cells
    Christian Jorgensen
    Service d Immuno Rhumatologie, Hopital Lapeyronie, 34295 Montpellier, Cedex 5, France
    Curr Opin Biotechnol 15:406-10. 2004
    ..The long-term behavior of MSCs associated with biomaterials and implanted in pathological joints remains to be investigated before clinical application in osteoarthritis or rheumatoid arthritis...
  24. ncbi request reprint Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis
    Farida Djouad
    INSERM U475, Montpellier, France
    Arthritis Rheum 52:1595-603. 2005
    ..Using a murine model of rheumatoid arthritis (RA), this study investigated whether the immunosuppressive properties of MSCs could be of therapeutic value to inhibit reactive T cells in autoimmune diseases such as RA...
  25. ncbi request reprint Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab
    Sylvie Fabre
    Department of Immuno Rheumatology, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
    J Rheumatol 32:2432-3. 2005
    ..We describe a patient receiving infliximab who developed a primary cutaneous Nocardia otitidiscaviarum infection after a skin injury...
  26. ncbi request reprint Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells
    Farida Djouad
    INSERM U475, Montpellier, France
    Transplantation 82:1060-6. 2006
    ..However, because of their immunosuppressive capacities, we investigated the effect of MSC on the development of syngeneic tumors...
  27. pmc Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes
    Farida Djouad
    INSERM, U 844, 80 avenue Augustin Fliche, Montpellier, F 34091 France
    Arthritis Res Ther 9:R33. 2007
    ..Our data suggest that crosstalk between ECM components of the microenvironment and MSCs within the cartilage is responsible for the differentiation of MSCs into chondrocytes...
  28. ncbi request reprint Tissue engineering through mesenchymal stem cells: role of the Genostem Consortium
    Christian Jorgensen
    Regen Med 1:493-6. 2006
  29. ncbi request reprint CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis
    Ursula Mason
    GlaxoSmithKline Pharmaceuticals, Greenford, Middlesex, UK
    J Rheumatol 29:220-9. 2002
    ..Double blind studies were conducted with the anti-CD4 monoclonal antibody (Mab) keliximab in patients with active, stable rheumatoid arthritis (RA), to confirm preliminary evidence of efficacy and safety from open. uncontrolled studies...